Kidney Disease

  • Margherita Rosa
  • Salvatore Di Giulio
Part of the Updates in Surgery book series (UPDATESSURG)


Crohn’s disease (CD) potentially affects many organs, including, albeit rarely, the kidney. The most frequent renal manifestations are calcium oxalate stones and their complications; secondary amyloidosis; acute tubular necrosis related to volume depletion caused by diarrheal fluid losses or inadequate fluid intake, or both. Tubulo-interstitial nephritis is another common finding and, among patients with CD, the most common cause is drug-related nephritis. However, case reports in the literature suggest that granulomatous interstitial nephritis is also an extraintestinal manifestation of CD. Glomerulonephritis has been reported in CD patients as well.


Familial Mediterranean Fever Interstitial Nephritis Systemic Amyloidosis Acute Interstitial Nephritis Extraintestinal Manifestation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Parks JH, Worcester EM, O’Connor RC et al (2003) Urine stone risk factors in nephrolithiasis patients with and without bowel disease. Kidney Int 63:255–265CrossRefPubMedGoogle Scholar
  2. 2.
    McConnell N, Campbell S, Gillanders I et al (2002) Risk factors for developing renal stones in inflammatory bowel disease. BJU Int 89:835–841CrossRefPubMedGoogle Scholar
  3. 3.
    Worcester EM (2002) Stones from bowel disease. Endocrinol Metab Clin North Am 31:979–999CrossRefPubMedGoogle Scholar
  4. 4.
    Kumar R, Ghoshal UC, Singh G et al (2004) Infrequency of colonization with Oxalobacter formigenes in inflammatory bowel disease: possible role in renal stone formation J Gastroenterol Hepatol 19:1403–1409CrossRefPubMedGoogle Scholar
  5. 5.
    Siva S, Barrack ER, Reddy GP et al (2009) A critical analysis of the role of gut Oxalobacter formigenes in oxalate stone disease. BJU Int 103:18–21CrossRefPubMedGoogle Scholar
  6. 6.
    Viana ML, Pontes RM, Garcia WE et al (2007) Crohn’s disease and kidney stones: much more than coincidence? Arch Gastroenterol 44:210–214Google Scholar
  7. 7.
    National Kidney Disease Education Program. Information of Health Professionals 2006 Creatinine Standardization Program. Accessed at Scholar
  8. 8.
    National Kidney Foundation (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Kidney Disease Outcome Quality Initiative. Am J Kidney Dis 39:S1–266Google Scholar
  9. 9.
    Cirillo M, Iudici M, Marcarelli F et al (2008) Nephrolithiasis in patients with intestinal diseases. G Ital Nefrol 25:42–48PubMedGoogle Scholar
  10. 10.
    Pak CY (2008) pharmacotherapy of kidney stones. Expert Opin Pharmacother 9: 1509–1518CrossRefPubMedGoogle Scholar
  11. 11.
    Lieske JC, Goldfarb DS, De Simone C et al (2005) Use of a probiotic to decrease enteric hyperoxaluria. Kidney Int 68:1244–1249CrossRefPubMedGoogle Scholar
  12. 12.
    Braden GL, O’Shea MH, Mulhern JG (2005) Tubulointerstitial diseases. Am J Kidney Dis 46:560–572CrossRefPubMedGoogle Scholar
  13. 13.
    Khan SR (2004) Crystal-induced inflammation of the kidneys: results from human studies, animal models, and tissue-culture studies. Clin Exp Nephrol 8:75–88CrossRefPubMedGoogle Scholar
  14. 14.
    Tintillier M, Pochet JM, Blackburn D et al (2001) Hyperoxaluria: an underestimated cause of rapidly progressive renal failure. Acta Clin Belg 56:360–363PubMedGoogle Scholar
  15. 15.
    Rossert J (2001) Drug-induced acute interstitial nephritis. Kidney Int 60:804–817CrossRefPubMedGoogle Scholar
  16. 16.
    Härmark L, van der Wiel HE, de Groot MC et al (2007) Proton pump inhibitor-induced acute interstitial nephritis. Br J Clin Pharmacol 64:819–823PubMedGoogle Scholar
  17. 17.
    González E, Gutiérrez E, Galeano C et al (2008) Early steroid treatment improves the recovery of renal function in patients with drug-induced acute interstitial nephritis. Kidney Int 73:940–946CrossRefPubMedGoogle Scholar
  18. 18.
    Van Staa TP, Travis S, Leufkens HG et al (2004) 5-aminosalicylic acids and the risk of renal disease: a large British epidemiologic study Gastroenterology 126:1733–1739CrossRefPubMedGoogle Scholar
  19. 19.
    Gisbert JP, González-Lama Y, Maté J (2007) 5-Aminosalicylate and renal function in inflammatory bowel disease: a systematic review. Inflamm Bowel Dis 13:629–638CrossRefPubMedGoogle Scholar
  20. 20.
    Corrigan G, Stevens PE (2000) Review article: interstitial nephritis associated with the use of mesalazine in inflammatory bowel disease. Aliment Pharmacol Ther 14:1–6CrossRefPubMedGoogle Scholar
  21. 21.
    Tadic M, Grgurevic I, Scukanec-Spoljar M et al (2005) Acute interstitial nephritis due to mesalazine. Nephrology 10:103–105CrossRefPubMedGoogle Scholar
  22. 22.
    Arend LJ, Springate JE (2004) Interstitial nephritis from mesalazine: case report and literature review. Pediatr Nephrol 19:550–553CrossRefPubMedGoogle Scholar
  23. 23.
    Sierra F, Suarez M, Rey M et al (2007). Systematic review: proton pump inhibitor-associated acute interstitial nephritis. Aliment Pharmacol Ther 26:545–553PubMedCrossRefGoogle Scholar
  24. 24.
    Joss N, Morris S, Young B et al (2007) Granulomatous interstitial nephritis. Clin J Am Soc Nephrol 2:222–230CrossRefPubMedGoogle Scholar
  25. 25.
    Archimandritis AJ, Weetch MS (1993) Kidney granuloma in Crohn’s disease. BMJ 307:540–541CrossRefPubMedGoogle Scholar
  26. 26.
    Béji S, Kaaroud H, Ben Moussa F et al (2004) Renal amyloidosis complicating the outcome of chronic inflammatory colitis. Presse Med 33:862CrossRefPubMedGoogle Scholar
  27. 27.
    Lovat LB, Madhoo S, Pepys MB et al (1997) Long term survival in systemic amyloid A amyloidosis complicating Crohn’s disease. Gastroenterology 112:1362–1365CrossRefPubMedGoogle Scholar
  28. 28.
    Dember LM (2006) Amyloidosis-associated kidney disease. J Am Soc Nephrol 17:3458–7341CrossRefPubMedGoogle Scholar
  29. 29.
    Park YK, Han DS, Eun CS (2008) Systemic amyloidosis with Crohn’s disease treated with infliximab. Inflamm Bowel Dis 14:431–432CrossRefPubMedGoogle Scholar
  30. 30.
    Petterson T, Konttinen YT, Maury CP (2008) Treatment strategies for amyloid A amyloidosis. Expert Opin Pharmacother 9:2117–2128CrossRefGoogle Scholar
  31. 31.
    Garrido Serrano A, Guerrero Igea FJ, Hierro Guilmain C et al (2001) Good response to colchicine in amyloidosis secondary to inflammatory bowel diseases. Gastroenterol Hepatol 24:196–198PubMedGoogle Scholar
  32. 32.
    Dember LM (2009) Modern treatment of amyloidosis: unresolved questions. J Am Soc Nephrol 20:469–472CrossRefPubMedGoogle Scholar
  33. 33.
    Gillmore JD, Lovat LB, Persey MR et al (2001) Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet 358:24–29CrossRefPubMedGoogle Scholar
  34. 34.
    Sherif AM, Refaie AF, Sobh MA et al (2003) Long-term outcome of live donor kidney transplantation for renal amyloidosis. Am J Kidney Dis 42:370–375CrossRefPubMedGoogle Scholar
  35. 35.
    Takemura T, Okada M, Yagi K et al (2002) An adolescent with IgA nephropathy and Crohn disease: pathogenetic implications. Pediatr Nephrol 17:863–866CrossRefPubMedGoogle Scholar
  36. 36.
    Shaer AJ, Stewart LR, Cheek DE et al (2003) IgA antiglomerular basement membrane nephritis associated with Crohn’s disease: a case report and review of glomerulonephritis in inflammatory bowel disease. Am J Kidney Dis 41:1097–1109CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Italia 2010

Authors and Affiliations

  • Margherita Rosa
    • 1
  • Salvatore Di Giulio
    • 1
  1. 1.Nephrology and Dialysis Unit, Department of Nephrology, Dyalisis, Diabetology and TransplantationSan Camillo-Forlanini HospitalRomeItaly

Personalised recommendations